The latest biotech news - Labiotech.eu

Triastek sees positive results from printed oral treatment for ulcerative colitis

Jim Cornall — Tue, 25 Jul 2023 10:22:26 +0000

Triastek, Inc. has completed its first in human study of its third 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC). Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug release. The administration of […]

The post Triastek sees positive results from printed oral treatment for ulcerative colitis appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Can the microbiome help the fight against infections?

Jim Cornall — Tue, 25 Jul 2023 09:30:00 +0000

Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […]

The post Can the microbiome help the fight against infections? appeared first on Labiotech.eu.

Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial

Jim Cornall — Tue, 25 Jul 2023 09:15:00 +0000

Molecure S.A. has received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to conduct phase II clinical testing of OATD-01. The announcement follows the company closing a secondary public offering and entering into subscription agreements for all 2,776,000 H-shares offered by way of private placement, within the […]

The post Molecure raises $12M and gets FDA clearance for pulmonary sarcoidosis trial appeared first on Labiotech.eu.

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Jim Cornall — Tue, 25 Jul 2023 09:00:00 +0000

Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […]

The post Roche and Alnylam to work on RNAi therapeutic to treat hypertension appeared first on Labiotech.eu.

Crescendo Biologics raises $32M and expands cancer trial

Jim Cornall — Tue, 25 Jul 2023 08:21:48 +0000

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […]

The post Crescendo Biologics raises $32M and expands cancer trial appeared first on Labiotech.eu.

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

Jim Cornall — Thu, 20 Jul 2023 17:00:00 +0000

CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […]

The post CatalYm shows importance of GDF-15 in tumor immunotherapy resistance appeared first on Labiotech.eu.

Endometrial cancer drug receives breakthrough therapy designation in China

Jim Cornall — Thu, 20 Jul 2023 15:36:06 +0000

HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […]

The post Endometrial cancer drug receives breakthrough therapy designation in China appeared first on Labiotech.eu.

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

Jim Cornall — Thu, 20 Jul 2023 15:00:00 +0000

TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […]

The post Mage Biologics created to develop oral antibody therapy for ulcerative colitis appeared first on Labiotech.eu.

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

Biomica announces interim positive results from irritable bowel syndrome program

Jim Cornall — Thu, 20 Jul 2023 10:00:00 +0000

Biomica Ltd., a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, has released interim positive results from pre-clinical studies in its irritable bowel syndrome (IBS) program. The work was performed in collaboration with the lab of Kara Gross Margolis, associate director for clinical and translational research for the New York University Pain Research Center and an associate […]

The post Biomica announces interim positive results from irritable bowel syndrome program appeared first on Labiotech.eu.

Sosei Heptares hails ‘transformational’ acquisition

Jim Cornall — Thu, 20 Jul 2023 09:34:31 +0000

Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […]

The post Sosei Heptares hails ‘transformational’ acquisition appeared first on Labiotech.eu.

Novel bacterial communication system could help take on antimicrobial resistance

Jim Cornall — Wed, 19 Jul 2023 10:30:00 +0000

A new stress signaling system enables bacteria cells to adapt and protect themselves against the immune system and certain antibiotics. The discovery was made by researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for Environmental […]

The post Novel bacterial communication system could help take on antimicrobial resistance appeared first on Labiotech.eu.

Moleculin issues acute myeloid leukemia drug data

Jim Cornall — Wed, 19 Jul 2023 09:24:12 +0000

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […]

The post Moleculin issues acute myeloid leukemia drug data appeared first on Labiotech.eu.

Korro Bio and Frequency Therapeutics to merge

Jim Cornall — Tue, 18 Jul 2023 09:47:03 +0000

Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to […]

The post Korro Bio and Frequency Therapeutics to merge appeared first on Labiotech.eu.

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

Jim Cornall — Tue, 18 Jul 2023 09:00:00 +0000

DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […]

The post Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma appeared first on Labiotech.eu.

FDA approves Beyfortus ahead of 2023-24 RSV season

Jim Cornall — Tue, 18 Jul 2023 08:28:06 +0000

The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]

The post FDA approves Beyfortus ahead of 2023-24 RSV season appeared first on Labiotech.eu.

Hope for Alzheimer’s patients after Lilly drug results

Jim Cornall — Mon, 17 Jul 2023 16:15:00 +0000

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

The post Hope for Alzheimer’s patients after Lilly drug results appeared first on Labiotech.eu.

Westlake launches $450M fund for LA biotechs

Jim Cornall — Mon, 17 Jul 2023 16:00:00 +0000

Westlake Village BioPartners has launched its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond. The new fund will be managed by founding managing director Beth Seidenberg, managing director Mira Chaurushiya, and David Allison, who was recently appointed managing director. “This new fund […]

The post Westlake launches $450M fund for LA biotechs appeared first on Labiotech.eu.

Lilly boosts obesity portfolio with Versanis Bio acquisition

Jim Cornall — Mon, 17 Jul 2023 15:25:13 +0000

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]

The post Lilly boosts obesity portfolio with Versanis Bio acquisition appeared first on Labiotech.eu.

Life saved: AI discovers existing drug works for rare disease

Jim Cornall — Fri, 14 Jul 2023 09:45:00 +0000

A patient’s life was saved after researchers at the University of Pennsylvania, Castleman Disease Collaborative Network, Medidata, and Every Cure, used artificial intelligence to use an existing drug to treat idiopathic multicentric Castleman disease (iMCD). Every Cure and its partners are developing medical databases and AI algorithms to unlock new uses for existing medicines across […]

The post Life saved: AI discovers existing drug works for rare disease appeared first on Labiotech.eu.